Lon R. Greenberg
Known title: DirectorCIK: 0001234234
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ameriprise Financial Adds Advisor Teams, Optimism Before Earnings. Ameriprise Financial welcomed three financial advisor teams from RBC Capital Markets, representing nearly $1.2 billion in assets. The company is also seeing renewed analyst optimism ahead of its Q3 2026 earnings release, alongside its $5.5 billion share repurchase authorization. These developments highlight the firm's advisor network expansion and capital return plans.
Transaction History
| COR | ▼ Sell | Open Market | 1,280 | $411K | 9/16/2026 | View on chart |
| COR | ▲ Buy | Grant | 557 | $200K | 3/5/2026 | View on chart |
| COR | ▼ Sell | Open Market | 3,000 | $837K | 5/14/2025 | View on chart |
| COR | ▲ Buy | Grant | 789 | — | 3/6/2025 | View on chart |
| COR | ▼ Sell | Gift | 5,000 | $0 | 8/5/2024 | View on chart |
| COR | ▲ Buy | Grant | 843 | — | 3/12/2024 | View on chart |
| COR | ▲ Buy | Option Exercise | 1,340 | $294K | 1/15/2024 | View on chart |
| COR | ▼ Sell | Gift | 2,000 | $0 | 10/20/2023 | View on chart |
| COR | ▲ Buy | Grant | 1,334 | — | 3/9/2023 | View on chart |
| COR | ▲ Buy | Option Exercise | 1,360 | — | 1/17/2023 | View on chart |
| COR | ▲ Buy | Option Exercise | 1,417 | — | 1/15/2022 | View on chart |
| AMP | ▼ Sell | Gift | 2,500 | $0 | 9/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects
Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.
Cencora Valuation and AI Impact: Analysts Debate Growth Prospects. Recent analyses debate whether Cencora is undervalued or if its raised guidance is already priced in, as the stock trades near its 52-week high and average analyst target. Other reports suggest the company's distribution model could benefit more from AI disruption than certain telehealth competitors. The stock is also compared to major pharmaceutical companies like AbbVie and Eli Lilly as market participants assess the healthcare sector.